AR and breast cancer: ER-alpha, PR and GATA3 were as expected among the top proteins overexpressed in the Luminal subtype, as well as androgen receptor (AR)15 and Bcl-216, two therapeutic targets under development in ER+/HER2 BC, whereas PARP1 was among the top proteins overexpressed in the Basal samples.